Downregulation and growth inhibitory role of FHL1 in lung cancer

• DOI: 10.1002/ijc.26259
• Publication Date: 2011-06-23T13:56:39Z
• Authors: Chang Niu; Chaoyang Liang; Juntang Guo; Long Cheng; Hao Zhang; Xi Qin; Qunwei Zhang; Lihua Ding; Bin Yuan; Xiaojie Xu; Jiezhi Li; Jing Lin; Qinong Ye
• Keywords: Adult; Male; 0301 basic medicine; Lung Neoplasms; Tumor Suppressor Proteins; Intracellular Signaling Peptides and Proteins; Down-Regulation; Muscle Proteins; Cell Cycle Checkpoints; Mice, SCID; LIM Domain Proteins; Middle Aged; 3. Good health; Mice; 03 medical and health sciences; Cell Line, Tumor; Animals; Humans; Female; Aged

AbstractFour and a half Lin‐11, Isl‐1, Mac‐3 (LIM) protein 1 (FHL1) has been linked to carcinogenesis. However, the role of FHL1 in lung cancer remains unclear and the detailed mechanism underlying its tumor suppressive role is poorly understood. The purpose of this study was to examine FHL1 expression in lung cancer patients and to investigate how it was associated with lung cancer cell growth. Immunoblotting and immunohistochemistry showed that FHL1 protein was downregulated in over 90% of 80 lung cancer patients. FHL1 expression was strongly correlated with tumor histological types (p < 10−4) and the differentiation of the tumor (p = 0.002). FHL1 inhibited anchorage‐dependent and ‐independent growth of human lung cancer cell lines. The inhibitory effects of FHL1 on lung cancer cell growth were associated with both the G1 and the G2/M cell cycle arrest concomitant with a marked inhibition of cyclin A, cyclin B1 and cyclin D as well as the induction of the cyclin dependent kinase inhibitors p21 (WAF1/CIP1) and p27 (Kip1). Direct intratumoral injection of an adenovirus expressing FHL1 dramatically suppressed the growth of A549 lung cancer cells in nude mice. Our data suggest that reduced expression of FHL1 may play an important role in the development and progression of lung cancer and that FHL1 may be a useful target for lung cancer gene therapy.